KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Gross Margin (2016 - 2025)

NovoCure's Gross Margin history spans 11 years, with the latest figure at 75.82% for Q4 2025.

  • For Q4 2025, Gross Margin fell 343.0% year-over-year to 75.82%; the TTM value through Dec 2025 reached 74.54%, down 280.0%, while the annual FY2025 figure was 74.54%, 280.0% down from the prior year.
  • Gross Margin for Q4 2025 was 75.82% at NovoCure, up from 73.25% in the prior quarter.
  • Across five years, Gross Margin topped out at 80.41% in Q1 2021 and bottomed at 73.01% in Q2 2023.
  • The 5-year median for Gross Margin is 77.07% (2024), against an average of 76.75%.
  • The largest annual shift saw Gross Margin surged 447bps in 2021 before it crashed -675bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 77.71% in 2021, then fell by 0bps to 77.51% in 2022, then decreased by -2bps to 75.67% in 2023, then rose by 5bps to 79.25% in 2024, then dropped by -4bps to 75.82% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Gross Margin are 75.82% (Q4 2025), 73.25% (Q3 2025), and 73.88% (Q2 2025).